James Peyer

All filings by James Peyer on record concern Faeth Therapeutics, Inc., in the capacity of board member. In total, 78 filings cover trades dated from 8 February 2021 to 9 December 2025.

In open-market terms, that means 64 purchases worth €3.6M on one side and 8 sales worth €247k on the other. Purchases outweigh sales by €3.3M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 3 share grants and 1 option exercise. 2025 to date brings no purchases and 8 sales.

A typical purchase (the median) is worth €39k. Relative to company size, the median is 0.077% of market cap (3 purchases with a known value). On 61 out of 61 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. After 29 purchases with a full 90-day history, the hit rate stands at 0% and the median 90-day move at -44.7%. They describe history only and say nothing certain about the share price ahead.

The record was last updated on 10 December 2025 with an open-market sale (€18k) in Faeth Therapeutics, Inc. The latest purchase dates back some time: it was published 1,613 days ago, on 10 June 2022. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.